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Available online 8 February 2014Pomiferin is a unique, prenylated isoflavonoid that can be isolated and purified from the fruits
of Maclura pomifera (Osage Orange). The molecule typically is isolated with a small amount of
a molecule called Osajin which is structurally similar to Pomiferin but lacks an aromatic
hydroxyl group. As a consequence, Osajin has been shown to be a less effective antioxidant
than Pomiferin. In vitro studies on Normal Human Dermal Fibroblasts demonstrate that
Pomiferin is a potent extracellular matrix protein stimulant, showing increases in collagen,
elastin and fibrillin expression comparable or superior to equivalent concentrations of retinol.
Ex vivo hair follicle assays demonstrate comparable effects on expression of collagen and
elastin at Pomiferin concentrations in the range of 0.05–5 ppm. Taken together, the results
from the two assays conducted on different models indicate that Pomiferin may be a very
interesting ingredient for topical skin and scalp treatmentswheremodulation of the expression of
extracellular matrix proteins is important.







Pomiferin is a prenylated isoflavonoid originally isolated
and identified from the fruits of Osage Orange (Maclura
pomifera) byWolfrom et al., in 1939 [1,2], Fig. 1A. The crystal
structure of Pomiferin, however, was not fully resolved until
2003 by Marek et al. [3]. Pomiferin is typically isolated with
another structurally similar prenylated isoflavonoid called
Osajin [4], Fig. 1B. Studies examining the antioxidant efficiency
of these two molecules have demonstrated that Pomiferin is a
stronger antioxidant than Osajin [5–7]. This is most likely
due to the molecular arrangement of Pomiferin that places
two hydroxyl groups on adjacent aromatic carbon atoms in
the B-ring. The molecular structure of adjacent conjugated
hydroxyl groups is common in strong antioxidants such as
EGCG and Vitamin C.: +1 618 258 6808.
er).
.V. Open access under CC BY-NCStudies on the influence of Pomiferin on various human
cell lines have been reported. In particular, some studies have
focused on the influence of Pomiferin on cancer cell lines
[8,9]. Svasti et al., examined the effects of Pomiferin on a
cholangiocarcinoma cell line, suggesting that the molecule
has the ability to kill such cells in vitro. Likewise, Yang et al.,
examined the effects of Pomiferin on breast epithelial cancer
cells suggesting that the molecule has selectivity towards
such cancer cells, again in in vitro assays. Moon et al.,
examined the effects of Pomiferin as a histone deacetylase
inhibitor on various cancer cell lines in vitro noting that
Pomiferin had the ability to inhibit histone deacetylase activity
which may correlate with inhibition of tumor growth [10]. To
date, there have been no clinical trials with Pomiferin as a
potential cancer treatment. In addition, Pomiferin has been
suggested to have antimicrobial efficacy against a number of
pathogenic microorganisms including Staphylococcus aureus,
Mycobacterium smegmatis. Escherichia coli, Klebsiella pneumoniae
and Staphylococcus gallinarum [11].-ND license.
Fig. 1. A–B, Pomiferin, R1, R2 = OH: Osajin, R1 = OH, R2 = H.
165J.V. Gruber et al. / Fitoterapia 94 (2014) 164–171Studies intended to examine the effects of Pomiferin on skin
cells have not been reported. Recently, Gruber et al., reported
on studies in which normal human dermal fibroblasts and
normal human epidermal keratinocyte were exposed to
Pomiferin (and Osajin) and gene arrays were run compar-
ing these molecules against a number of other popular skin
antioxidants including, for example, EGCG, rosavin, genis-
tein etc. [12]. However, these studies did not provide any
specific information on how Pomiferinmight actually influence
expression of skin extracellular matrix proteins like collagen
and elastin.
This paper will report on efforts to examine the effect of
Pomiferin on normal human dermal fibroblasts and normal
human epidermal keratinocytes to see if the molecule might
have benefits as a topical skin care active. This paper will
report for the first time on studies examining the influence of
Pomiferin to stimulate extracellular matrix protein expression,
in particular, type 1A1 collagen, elastin and fibrillin expression
in fibroblasts. Using an ex vivo hair follicle model, the effects of
Pomiferin on collagen expression noted in the fibroblasts in vitro
assay concurred with findings of the ex vivo hair follicles. Taken
together, the two assays suggest that Pomiferin may be a very
interesting ingredient for topical skin and scalp treatments.
2. Materials
2.1. Pomiferin and retinol
Pomiferin was purchased from Gaia Chemical (Gaylordsville,
CT) and was approximately 90% pure with the remaining 10%
being essentially Osajin. The material was used in the assays
without further purification. Commercially available retinol
(N95%) was purchased from Sigma-Aldrich (Milwaukee,WI)
and was used without further purification.
3. In vitro tissue equivalent experimental methods
3.1. Preparation of ﬁbroblasts
Human dermal fibroblasts were obtained from Cascade
Biologics and seeded into the individual wells of a 24-well
plate in 0.5 ml of Fibroblast Growth Media (FGM: DMEM
supplemented with 2% fetal bovine serum (FBS), 50 μg/ml
gentamicin, 250 μg/ml amphotericin B, 2 ng/ml human basicfibroblast growth factor, 10 μg/ml human Insulin) and incubat-
ed overnight at 37 ± 2 °C and 5 ± 1% CO2. On the following
day the media were removed via aspiration to eliminate any
non-adherent cells and replaced with 0.5 ml of fresh FGM. The
cells were grown until confluent, with amedia change every 48
to 72 h. Upon reaching confluency the cells were treated for
24 h with DMEM supplemented with 1.5% FBS to wash out any
effects from the growth factors included in the normal culture
media. After this 24-hour wash out period the cells were treated
with the test materials at the specified concentrations dissolved
in DMEMwith 1.5% FBS. Retinol was used as a positive control in
all the in vitro studies. Untreated cells (negative controls)
received DMEM with 1.5% FBS. The cells were incubated for
48 h and at the end of the incubation period cell culturemedium
was collected and either stored frozen (−75 °C) or assayed
immediately.
3.2. MTT assay
After the 2-day incubation, the cell culture medium was
removed (see above) and the fibroblasts were washed twice
with PBS to remove any remaining test material. After the
final wash, 500 μl of DMEM supplemented with 0.5 mg/ml
MTT was added to each well and the cells were incubated for
1 h at 37 ± 2 °C and 5 ± 1% CO2. After the incubation, the
DMEM/MTT solution was removed and the cells were washed
again once with PBS and then 1 ml of isopropyl alcohol was
added to the well to extract the purple formazin crystals. Two
hundred microliters of the isopropyl extracts was transferred
to a 96-well plate and the plate was read at 540 nm using
isopropyl alcohol as a blank.
3.3. Procollagen ELISA
Media samples were assayed for type I collagen produc-
tion using a Type I C-Peptide ELISA kit from Takara Bio Inc.
per the manufacturer's instructions.
3.4. Elastin ELISA
Soluble α-elastin from Sigma Chemical was dissolved
in 0.1 M sodium carbonate (pH 9.0) at a concentration of
1.25 μg/ml. 150 μl of this solution was then applied to the
wells of a 96-well maxisorp Nunc plate and the plate was
incubated overnight at 4 °C. On the following day the wells
were saturated with PBS containing 0.25% BSA and 0.05%
Tween 20. The plate was then incubated with this blocking
solution for 1 h at 37 °C and then washed two times with
PBS containing 0.05% Tween 20.
A set of α-elastin standards was generated ranging from
0 to 100 ng/ml (prepared in DMEM + 1.5% FBS). 180 μl of
either standard or spent media sample from the fibroblasts
undergoing the various treatments was then transferred to a
650 μl microcentrifuge tube. An anti-elastin antibody solu-
tion was prepared (the antibody was diluted 1:100 in PBS
containing 0.25% BSA and 0.05% Tween 20) and 20 μl of the
solution was added to the tube. The tubes were then incubated
overnight at 4 ± 2 °C. On the following day, 150 μl was trans-
ferred fromeach tube to the 96-well elastin ELISAplate, and the
platewas incubated for 1 h at room temperature. The platewas
then washed 3 times with PBS containing 0.05% Tween 20.
Fig. 2. Results of fibroblast viability assays.
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linked secondary antibody diluted in PBS containing 0.25% BSA
and 0.05% Tween 20 was added, and the plate was incubated
for 1 h at room temperature. After washing the plate three
times as described above, 200 μl of a substrate solution was
added and the plate was incubated for 10 to 30 min in the dark
at room temperature. After this final incubation the plate was
read at 460 nm using a plate reader.
3.5. Fibrillin assay
A PVDF membrane was prewet in methanol, equilibrat-
ed with TBS (TBS: 20 mM Tris, pH 7.5, 150 mM NaCl) and
assembled into the Bio-Dot microfiltration apparatus. After
assembly, 100 μl of TBS was added to the wells in the Bio-
Dot and the vacuum was applied to ensure that there was
an adequate flow through all of the wells. Next, 250 μl of
each spent media sample from the fibroblasts undergoing
the various treatments was assigned a well in the apparatus
and the sample was applied to the appropriate well. After
all of the samples had been added, a vacuumwas applied toFig. 3. Results of Type 1A1the apparatus to draw the fluid of the samples through the
membrane, leaving the protein adhered to the membrane.
TBS was added to wells not assigned a sample to ensure
that the membrane did not dry out during the procedure.
At the end of the blotting procedure the membrane was
removed from the Bio-Dot apparatus, washed in TBS for
5–10 min and then placed into blocking solution (TBS with
1% non-fat milk powder) and allowed to incubate for at
least 1 h at room temperature on a rocking platform.
After blocking, the membrane was transferred to 20 ml of
TBST (TBS with 0.1% Tween-20) and 0.1% non-fat powdered
milk with an appropriate dilution of antibody and allowed to
incubate overnight at 4 °C on a rocking platform. After this
incubation the membrane was washed 3 times (1 for 15 min
and 2× for 5 min) in TBST. The secondary antibody (conjugated
with a fluorophore) was then incubated with themembrane in
15 ml of TBSTwith 0.1% non-fat powderedmilk for 1 h at room
temperature and then washed 3 times with TBS (1× 15 min,
2× for 5 min).
After the final wash, themembrane was placed into a BioRad
Molecular Imager FX and scanned using an excitation laser andProcollagen assay.
Fig. 4. Results of elastin assay.
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Images produced by the scanner were then analyzed using
ImageJ image analysis software.3.6. Calculations
The mean MTT absorbance value for the negative control
cells was calculated and used to represent 100% cell viability.
The individualMTT values from the cells undergoing the various
treatments were then divided by the mean value for the neg-
ative control cells and expressed as a percent to determine the
change in cell viability caused by each treatment.
For the collagen and elastin ELISA assays, to quantify the
amount of each substance present in the spent media samples,
a standard curve was generated using known concentrations
of each substance and the equation for the line which best fit
these standard curve was determined using a regression anal-
ysis. For the fibrillin assay, mean fluorescence intensity scores
were used for comparison purposes. For all of the assays, mean
values were compared using a one way ANOVA. In the results
section, statistically significant differences (P b 0.05) between aFig. 5. Results of fibspecific treatment and the untreated group are designatedwith
an asterisk.4. Ex vivo hair follicle growth assay
4.1. Isolation of human Anagen IV hair follicles from culture
[13]
Normal human scalp tissue (58 y, Female with brown hair)
was sourced from elective plastic surgery. Scalp was cleaned
in wash solution and carefully sliced immediately below the
dermal/fat junction. AnagenVI hair follicleswere isolated under
a dissecting microscope and placed in Williams E Medium
(WEM; Sigma) containing 2× antibiotic/antifungals, 2 mM
Glutamax (Invitrogen, UK), 10 μg/ml Insulin and 10 ng/ml
Hydrocortisone. After isolation hair follicles were inspected
and any with signs of damage or catagen/telogen morphology
were discarded. Intact hair follicles were placed singly in a well
of a 48-well culture plate ensuring they were completely
submerged in 0.3 ml WEM. Hair follicles were placed in a
humidified tissue culture incubator at 37 °C containing 5%rillin assay.
Fig. 6. Measurement of hair elongation for various follicle treatments.
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that did not show overnight growth were discarded.
4.2. Pomiferin treatments
Aworking stock of 0.5% Pomiferin dissolved in ethyl lactate
was diluted in WEM to final test concentrations of 0.0005%,
0.00005% and 0.000005%. Three replicates of 10 follicles for
each treatment were incubated in 3 test concentrations of
Pomiferin in addition to ethyl lactate vehicle controls (0.1%)
and WEM alone. Hair follicles were incubated for 6 days and
photographed on day 0 prior to the start of the experiment and
at days 2, 4 and 6 (immediately prior to cryopreservation).
Growth was assessed bymeasuring elongation of the hair fiber
from the ‘shoulder’ which demarcated new growth since iso-
lation. Media were replenished on days 2 and 4. Hair follicles
were collected for analysis by snap freezing in a small amount
of OCT freezing medium. OCT embedded hair follicles were
stored at−80 °C until cryosectioning.
4.3. Immunocytochemistry
For immunocytochemistry 10 μm sections were cut and
mounted on charged slides (Leica, UK). Sections were air-dried
at RT then fixed in ice-cold acetone for 10 min at−20 °C. After
equilibrating to RT slides were rinsed in PBS. Non-specific
antibody binding was blocked by incubating in 10% donkey
serum (Sigma-Aldrich, UK) diluted in PBS for at least 30 min.
Serum was poured off and followed by incubation in primary
antibody (Tropoelastin (1:100, ab-21605), Elastin (1:100, ab-23747) and Collagen-1 (1:100 and 1:500, ab-34710); Abcam,
UK) diluted in PBS containing 1% donkey serum overnight in a
humidified slide chamber at 4 °C. Excess primary antibody was
rinsed by washing in PBS for 3 × 10 min. Hair follicles were
incubated in donkey anti-rabbit Alexa-488 conjugated second-
ary antibody (Invitrogen Molecular Probes, UK) for 1 h at RT
then rinsed in PBS for 4 × 10 min. Slides were mounted for
confocal microscopy under sealed coverslips in fluorescent
mounting medium containing DAPI nuclear stain (VectorLabs,
UK). Images were collected using the 365 nm (UV) and
488 nm (FITC) channels on a Zeiss LSM confocal microscope
by sequential line scanning. Images were processed using
the LSM confocal image browser software (Zeiss, UK) and
ImageJ (freeware).
4.4. Statistical analysis
Hair fiber elongation data were analyzed for statistical sig-
nificance using one-way ANOVA with Bonferroni post T-test
comparison (PRISM software).
5. Results and discussion
5.1. In vitro ﬁbroblasts assays
Results of the cytotoxicity of Pomiferin on Normal Human
Dermal Fibroblasts using MTT assay procedures are shown
below (Fig. 2). Pomiferin is well tolerated by the cells at
concentrations below 0.0005%. It has similar cytotoxicity to
retinol at comparable concentrations of 0.000026%.
Fig. 7. Photomicrographs of hair follicle histology after treatment with media and ethyl lactate (top) and media, ethyl lactate solvent and Pomiferin (at two
concentrations) and immunoprobed for collagen (green). Red indicates nuclei (TOTO-3).
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Fig. 8. Photomicrographs of hair follicle histology after treatment with media and ethyl lactate (top) and media, ethyl lactate solvent and Pomiferin (at two
concentrations) and immunoprobed for elastin (green). Red indicates nuclei (TOTO-3).
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(Fig. 3). Pomiferin had a significant impact on Type 1A1 Procol-
lagen expression in dermal fibroblasts. The results indicate a
significant effect of retinol at the 0.000026% equivalent treat-
ment levels. While both Pomiferin and retinol demonstrated
low cell toxicity at 0.000026%, the results of the retinol treat-
ments indicate a possible cytotoxic effect as collagen expression
dropped below untreated levels. This did not happen for
Pomiferin until concentrations approaching cytoxicity at
0.0005%.
Results of the elastin assay are shown below (Fig. 4).
Results from the elastin assay show a comparable effect of
treatment with Pomiferin and retinol at 0.000026%. Both
molecules stimulated elastin expression in fibroblasts.
Results of the fibrillin protein assay are shown below
(Fig. 5). Pomiferin treatment increased fibrillin protein
expression in fibroblasts, and was equivalent to retinol at
the 0.000026% treatment level.
5.2. Ex vivo hair follicle growth assays
Results of the influence of Pomiferin on hair elongation
are shown (Fig. 6). At concentrations shown to be cytotoxic
to fibroblasts in vitro (0.0005%), Pomiferin also showed a
suppression of hair fiber elongation as might be anticipated.
However, compared against the media and solvent (ethyl
lactate) alone which showed a slight suppression of elonga-
tion, Pomiferin at 0.00005% demonstrated a possible ability
to elongate ex vivo hair fibers although the increase in length
did not exceed that seen when hair follicles were treated
with medium — without ethyl lactate. Statistical analysis
(P b 0.05) demonstrated a significant increase in hair fiber
length when treated with 0.00005% Pomiferin compared to
treatment with media/ethyl lactate-media (Fig. 6).
Histological examination of hair follicles comparing media/
ethyl lactate-treated follicles against media/ethyl lactate/
Pomiferin-treated hair follicles demonstrates a significant
increase in collagen expression in the hair follicles as shown
below (Fig. 7). Histological examination of treated hair follicles
using collagen-specific immunochemical staining indicates an
apparent increase in collagen expression around thehair follicle
dermal sheath as indicated by a brighter green fluorescence for
the Pomiferin-treated follicles versus the hair follicles treated
withmedia and solvent alone at both Pomiferin concentrations.
Expression of collagen in the Pomiferin-treated follicles appearsstronger at 0.00005% versus 0.000005% showing effects com-
parable to collagen expression in dermal fibroblasts (Fig. 3).
Results from the two separate assays correlate well, and in-
dicate that Pomiferin can have a positive effect on collagen
expression both in vitro and ex vivo at concentrations in the
range of 5.0–0.05 ppm.
Results of elastin expression in the hair follicles are shown
below (Fig. 8). Results of elastin immunochemical staining
indicate that Pomiferin also can stimulate elastin expression
around the hair follicle at the 0.0005% level (near fibroblast
cytotoxic levels) but that it drops off at 0.00005%.
Pomiferin has been shown to be a potent upregulator of
extracellular matrix proteins both in vitro on dermal fibroblasts
and ex vivo on hair follicles. The results on dermal fibroblasts
indicate that the protein expression is equal to or superior to
retinol at comparable concentrations. This suggests that highly
purified Pomiferin might be an interesting ingredient for po-
tential skin and scalp care topical treatments where extracel-
lular matrix protein expression is strategically important.
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